Comparative Pharmacology
Head-to-head clinical analysis: CONEXXENCE versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONEXXENCE versus NORTREL 1 35 21.
CONEXXENCE vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive